Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure-Activity Relationship and Preclinical Characterization

被引:19
|
作者
Sinha, Neelima [1 ]
Karche, Navnath P. [1 ]
Verma, Mahip Kalyan [1 ]
Walunj, Sameer S. [1 ]
Nigade, Prashant B. [1 ]
Jana, Gourhari [1 ]
Kurhade, Sanjay P. [1 ]
Hajare, Anil K. [1 ]
Tilekar, Ajay R. [1 ]
Jadhav, Ganesh R. [1 ]
Thube, Baban R. [1 ]
Shaikh, Javed S. [1 ]
Balgude, Sudhakar [1 ]
Singh, Lairikyengbam Bikramjit [1 ]
Mahimane, Vijaya [1 ]
Adurkar, Shridhar K. [1 ]
Hatnapure, Girish [1 ]
Raje, Firoj [1 ]
Bhosale, Yogesh [1 ]
Bhanage, Dnyaneshwar [1 ]
Sachchidanand, Sachchidanand [1 ]
Dixit, Ruchi [1 ]
Gupta, Rajesh [1 ]
Bokare, Anand M. [1 ]
Dandekar, Manoj [1 ]
Bharne, Ashish [1 ]
Chatterjee, Manavi [1 ]
Desai, Sagar [1 ]
Koul, Sarita [1 ]
Modi, Dipak [1 ]
Mehta, Maneesh [1 ]
Patil, Vinod [1 ]
Singh, Minakshi [1 ]
Gundu, Jayasagar [1 ]
Goel, Rajan N. [1 ]
Shah, Chirag [1 ]
Sharma, Sharad [1 ]
Bakhle, Dhananjay [1 ]
Kamboj, Rajender Kumar [1 ]
Palle, Venkata P. [1 ]
机构
[1] Lupin Ltd, Lupin Res Pk, Novel Drug Discovery & Dev, Survey 46 A-47 A, Pune 412115, Maharashtra, India
关键词
COGNITIVE IMPAIRMENT; PARTIAL AGONIST; SCHIZOPHRENIA; TRANSMISSION; SELECTIVITY; ACTIVATION; EVP-6124; RODENTS; SAFETY; MEMORY;
D O I
10.1021/acs.jmedchem.9b01569
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The discovery of a series of thiophenephenyl-sulfonamides as positive allosteric modulators (PAM) of alpha 7 nicotinic acetylcholine receptor (alpha 7 nAChR) is described. Optimization of this series led to identification of compound 28, a novel PAM of alpha 7 nicotinic acetylcholine receptor (alpha 7 nAChR). Compound 28 showed good in vitro potency, with pharmacokinetic profile across species with excellent brain penetration and residence time. Compound 28 robustly reversed the cognitive deficits in episodic/working memory in both time-delay and scopolamine-induced amnesia paradigms in the novel object and social recognition tasks, at very low dose levels. Additionally, compound 28 has shown excellent safety profile in phase 1 clinical trials and is being evaluated for efficacy and safety as monotherapy in patients with mild to moderate Alzheimer's disease.
引用
收藏
页码:944 / 960
页数:17
相关论文
共 45 条